Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 2025European Heart Journal Supplements

Atherosclerotic cardiovascular events associated with BTK inhibitors: a systematic review and meta-analysis of harms

View Full Paper
Ask AI
Bookmark
Share

Authors

JAJoachim AlexandreDLDamien LegalloisCDCharles Dolladille

Discussion

Loading...

Member takes

Overview

Systematic review highlights increased atherosclerotic cardiovascular events linked to BTK inhibitors in patients with B-cell malignancies, suggesting safety concerns.

Key Points

  • BTK inhibitors significantly increased the risk of atherosclerotic cardiovascular events in phase 3 RCTs.
  • In the analysis, 6,838 patients were enrolled, with 55.2% receiving BTK inhibitors.
  • The risk difference for atherosclerotic cardiovascular events was 0.03, indicating a notable effect.
  • Despite benefits in treating B-cell malignancies, BTK inhibitors raise safety concerns regarding cardiovascular health.

Cite This Study

Alexandre et al. (2025) studied this question.

synapsesocial.com/papers/689a0c65e6551bb0af8cf980https://doi.org/10.1093/eurheartjsupp/suaf083.113
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Incidence of bleeding and hypertension in patients with hematologic malignancies treated with next-generation Bruton tyrosine kinase (BTK) inhibitors: A meta-analysis of randomized controlled trials2025
  2. 2Incidence of cardiac events associated with next-generation bruton tyrosine kinase (BTK) inhibitors compared to control in hematologic malignancies: A meta-analysis of randomized trials2025
  3. 3PO50 | Treatment with BTK inhibitors in patients affected by chronic lymphocytic leukemia: safety and hemostasis2025
  4. 4Number of patients needed to treat to prevent one atrial fibrillation event with zanubrutinib versus ibrutinib and acalabrutinib in B-cell malignancies2025
  5. 5Adverse event profiles of acalabrutinib and zanubrutinib in chronic lymphocytic leukemia: A real-world comparison2025 · 1 citations